Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in ZURA held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | MONTANOVA CAPITAL, LLC | 9.4M | $55.7M | +4.2% | 9.940% | 1.02% |
| 2 | Venrock Adviser, LLC | 6.4M | $38.0M | 0.0% | 6.774% | 1.15% |
| 3 | MPM BioImpact LLC | 4.5M | $26.4M | — | 4.708% | 1.61% |
| 4 | GREAT POINT PARTNERS LLC | 4.2M | $24.9M | 0.0% | 4.438% | 4.70% |
| 5 | JPMORGAN CHASE & CO | 4.4M | $24.5M | -2.3% | 4.584% | 0.00% |
| 6 | BRAIDWELL LP | 4.0M | $23.5M | -0.2% | 4.190% | 0.87% |
| 7 | Siren, L.L.C. | 3.7M | $22.0M | 0.0% | 3.932% | 0.45% |
| 8 | BlackRock, Inc. | 3.6M | $21.3M | +690.3% | 3.805% | 0.00% |
| 9 | Commodore Capital LP | 3.3M | $19.2M | 0.0% | 3.421% | 1.14% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.8M | $16.2M | 0.0% | 2.895% | 0.02% |
| 11 | Saturn V Capital Management LP | 2.1M | $12.4M | +183.9% | 2.212% | 1.78% |
| 12 | QVT Financial LP | 1.9M | $11.2M | +44.6% | 1.995% | 0.66% |
| 13 | ADAR1 Capital Management, LLC | 1.8M | $10.4M | +179.1% | 1.852% | 0.48% |
| 14 | ARMISTICE CAPITAL, LLC | 1.6M | $9.7M | +8.6% | 1.722% | 0.12% |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 1.6M | $9.3M | +200.2% | 1.668% | 0.00% |
| 16 | Affinity Asset Advisors, LLC | 1.5M | $8.6M | -42.9% | 1.541% | 0.39% |
| 17 | STEMPOINT CAPITAL LP | 1.4M | $8.1M | +81.6% | 1.440% | 1.39% |
| 18 | Ikarian Capital, LLC | 1.2M | $7.2M | +2.1% | 1.283% | 0.77% |
| 19 | EcoR1 Capital, LLC | 1.2M | $7.0M | 0.0% | 1.242% | 0.34% |
| 20 | Vestal Point Capital, LP | 1.2M | $6.9M | +129.7% | 1.236% | 0.16% |
| 21 | STATE STREET CORP | 1.0M | $5.9M | +413.8% | 1.054% | 0.00% |
| 22 | Boxer Capital Management, LLC | 900K | $5.3M | 0.0% | 0.947% | 0.40% |
| 23 | VANGUARD CAPITAL MANAGEMENT LLC | 747K | $4.4M | +53.5% | 0.787% | 0.00% |
| 24 | GOLDMAN SACHS GROUP INC | 574K | $3.4M | +275.3% | 0.604% | 0.00% |
| 25 | FMR LLC | 528K | $3.1M | -0.2% | 0.556% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ZURA — a direct measure of their conviction.
Filings activity in ZURA during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 97 | +3.2% | 76.95% | +6.70 pp | $430M | +9.3% |
| Q1 2026 | 94 | +27% | 70.25% | +8.24 pp | $393M | +65% |
| Q4 2025 | 74 | +12% | 62.01% | 1.86 pp | $238M | +33% |
| Q3 2025 | 66 | +3.1% | 63.87% | +6.77 pp | $179M | +384% |
| Q2 2025 | 64 | 15% | 57.10% | 10.08 pp | $37M | 37% |
| Q1 2025 | 75 | 12% | 67.18% | +1.39 pp | $59M | 45% |
| Q4 2024 | 85 | +12% | 65.79% | +8.76 pp | $107M | 29% |
| Q3 2024 | 76 | — | 57.03% | — | $150M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.
Quick answers to the most common questions about buying ZURA stock.
Based on Q2 2026 13F filings, institutional ownership of Zura Bio Limited stands at 77.0%, held across 97 reporting institutions.
MONTANOVA CAPITAL, LLC is the largest reported institutional holder of ZURA, with approximately 9,443,001 shares worth $0.06B as of Q2 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of ZURA.
Our composite Smart Money Score for ZURA is 49 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
26 institutions opened new positions in ZURA during Q2 2026, while 21 fully exited. 32 added to existing positions and 39 trimmed.
ZURA institutional ownership rose by 6.70 percentage points quarter-over-quarter, with a net change of +3 holders.
The top 10 institutions account for 63.3% of all reported 13F value in ZURA, and the top 25 account for 89.5%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.